BAFNA PHARM. share price has plunged 5% and is presently trading at Rs 82.0.
Meanwhile, the BSE HEALTHCARE index is at 42,350.2 (up 0.4%).
Among the top losers in the BSE HEALTHCARE index today are SYNGENE INTERNATIONAL (down 2.9%) and GRANULES INDIA (down 2.2%).
Jubilant Pharmova (up 3.6%) and CAPLIN POINT (up 3.6%) are among the top gainers today.
Over the last one year, BAFNA PHARM. has moved down from Rs 110.1 to Rs 82.0, registering a loss of Rs 28.1 (down 25.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,099.5 to 42,350.2, registering a gain of 50.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 126.8%), Glenmark Pharma (up 125.4%) and SUVEN PHARMACEUTICALS (up 104.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,841.8 (up 0.2%).
The top gainers among the BSE Sensex today are Maruti Suzuki (up 2.1%) and L&T (up 1.9%). The most traded stocks in the BSE Sensex are ICICI Bank and Tata Steel.
In the meantime, NSE Nifty is at 25,040.5 (up 0.1%). Shriram Transport and SBI LIFE INSURANCE are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,433.3 to 81,841.8, registering a gain of 16,408.5 points (up 25.1%).
BAFNA PHARM. net profit fell 111.4% YoY to Rs -7 million for the quarter ended June 2024, compared to a profit of Rs 64 million a year ago. Net sales declined 20.6% to Rs 333 million during the period as against Rs 419 million in April-June 2023.
For the year ended March 2023, BAFNA PHARM. reported 117.3% increase in net profit to Rs 113 million compared to net profit of Rs 52 million during FY22. Revenue of the company grew 35.5% to Rs 1,153 million during FY23.
The current Price to earnings ratio of BAFNA PHARM., based on rolling 12 month earnings, stands at 708.1.
Equitymaster requests your view! Post a comment on "BAFNA PHARM. Plunges 5%; BSE HEALTHCARE Index Up 0.4%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!